Riyaz Shah, Consultant Medical Oncologist at Cromwell Hospital , shared a post on X:
“First line lorlatinib in ALK+ cases. CROWN indication now approved in NHS England.
Blueteq reimbursement criteria are an interesting read especially bit about previous ALKi exposure and brain mets.”
More posts featuring R. Shah on OncoDaily.
